Reversing endogenous alloreactive B cell GC responses with anti-CD154 or CTLA-4Ig

American Journal of Transplantation

Volumn 13, Issue 9, 2013, Pages 2280-2292

  Chen, J ^a   Yin, H ^a   Xu, J ^a   Wang, Q ^a   Edelblum, K L ^a   Sciammas, R ^a   Chong, A S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Allograft rejection; alloreactive B cells; anti CD154; CTLA 4Ig; GC; MHC Class I tetramers; PCs

Indexed keywords

ANTIBODY; CD154 ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FLUOROCHROME; IMMUNOGLOBULIN G; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TETRAMER; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CELL COUNT; CELL DIFFERENTIATION; CELL EXPANSION; CELL MATURATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FOLLICULAR DENDRITIC CELL; GERMINAL CENTER; HEART TRANSPLANTATION; HUMAN; HUMAN CELL; IMMUNIZATION; IN VIVO STUDY; MEMORY CELL; MOUSE; NONHUMAN; PHENOTYPE; PLASMA CELL; PRIORITY JOURNAL; SPLEEN CELL; THERAPY;

ALLOGRAFT REJECTION; ALLOREACTIVE B CELLS; ANTI-CD154; CTLA-4IG; GC; MHC CLASS I TETRAMERS; PCS;

ANIMALS; B-LYMPHOCYTES; CD40 LIGAND; CTLA-4 ANTIGEN; GERMINAL CENTER; HEART TRANSPLANTATION; IMMUNOGLOBULINS; ISOANTIBODIES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; TRANSPLANTATION, HOMOLOGOUS;

EID: 84883453086     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12350     Document Type: Article

References (50)

1. Gloor JM, Winters JL, Cornell LD, et al. Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant 2010; 10: 582-589.
2. Smith RN, Colvin RB., Chronic alloantibody mediated rejection. Semin Immunol 2012; 24: 115-121.
3. Colvin RB, Smith RN., Antibody-mediated organ-allograft rejection. Nat Rev Immunol 2005; 5: 807-817.
4. Sellares J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: The dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012; 12: 388-399.
5. Everly MJ., Donor-specific anti-HLA antibody monitoring and removal in solid organ transplant recipients. Clin Transplant 2011; 24: 319-325.
6. Stegall MD, Gloor JM., Deciphering antibody-mediated rejection: New insights into mechanisms and treatment. Curr Opin Organ Transplant 2010; 15: 8-10.
7. Walsh RC, Alloway RR, Girnita AL, Woodle ES., Proteasome inhibitor-based therapy for antibody-mediated rejection. Kidney Int 2012; 81: 1067-1074.
8. Snanoudj R, Candon S, Legendre C., Targeting B cells in sensitized kidney transplant patients: State of the art and future perspectives. Curr Opin Organ Transplant 2010; 11: 2635-2646.
9. Mulder A, Eijsink C, Kardol MJ, et al. Identification, isolation, and culture of HLA-A2-specific B lymphocytes using MHC Class I tetramers. J Immunol 2003; 171: 6599-6603.
10. Li Y, Ma L, Yin D, Shen J, Chong AS., Long-term control of alloreactive B cell responses by the suppression of T cell help. J Immunol 2008; 180: 6077-6084.
11. Parsons RF, Vivek K, Rostami SY, et al. Acquisition of humoral transplantation tolerance upon de novo emergence of B lymphocytes. J Immunol 2011; 186: 614-620.
12. Pape KA, Kouskoff V, Nemazee D, et al. Visualization of the genesis and fate of isotype-switched B cells during a primary immune response. J Exp Med 2003; 197: 1677-1687.
13. Pape KA, Taylor JJ, Maul RW, Gearhart PJ, Jenkins MK., Different B cell populations mediate early and late memory during an endogenous immune response. Science 2011; 331: 1203-1207.
14. Park MS, Terasaki PI, Barbetti A, Han H, Cecka JM., Significance of the HLA molecular structure to transplantation. Clin Transpl 1988; 301-328.
15. Kaneku H., Impact of donor-specific HLA antibodies in transplantation, a review of the literature published in the last 3 years. Clin Transplant 2010; 283-306.
16. Altman JD, Davis MM., MHC-peptide tetramers to visualize antigen-specific T cells. Curr Protoc Immunol 2003; Chapter 17: Unit 17.3.
17. Nepom GT., MHC Class II tetramers. J Immunol 2012; 188: 2477-2482.
18. Eijsink C, Kester MG, et al. Rapid assessment of the antigenic integrity of tetrameric HLA complexes by human monoclonal HLA antibodies. J Immunol Methods 2006; 315: 153-161.
19. Zachary AA, Kopchaliiska D, Montgomery RA, Melancon JK, Leffell MS., HLA-specific B cells. II. Application to transplantation. Transplantation 2007; 83: 989-994.
20. Zachary AA, Kopchaliiska D, Montgomery RA, Leffell MS., HLA-specific B cells. I. A method for their detection, quantification, and isolation using HLA tetramers. Transplantation 2007; 83: 982-988.
21. Panoskaltsis-Mortari A, Taylor PA, Riddle MJ, Shlomchik MA, Blazar BR., In situ identification of allospecific B cells using pentamers. Blood 2008; 111: 3904-3905.
22. Kwun J, Oh BC, Gibby AC, et al. Patterns of de novo allo b cells and antibody formation in chronic cardiac allograft rejection after alemtuzumab treatment. Am J Transplant. 2012.
23. Goodnow CC, Vinuesa CG, Randall KL, Mackay F, Brink R., Control systems and decision making for antibody production. Nat Immunol 2010; 11: 681-688.
24. Cyster JG., B cell follicles and antigen encounters of the third kind. Nat Immunol 2010; 11: 989-996.
25. Kessler B, Michielin O, Blanchard CL, et al. T cell recognition of hapten. Anatomy of T cell receptor binding of a H-2kd-associated photoreactive peptide derivative. J Biol Chem 1999; 274: 3622-3631.
26. Blaney JE Jr., Nobusawa E, Brehm MA, et al. Immunization with a single major histocompatibility complex class I-restricted cytotoxic T-lymphocyte recognition epitope of herpes simplex virus type 2 confers protective immunity. J Virol 1998; 72: 9567-9574.
27. Yin D, Dujovny N, Ma L, et al. IFN-gamma production is specifically regulated by IL-10 in mice made tolerant with anti-CD40 ligand antibody and intact active bone. J Immunol 2003; 170: 853-860.
28. Townsend SE, Goodnow CC, Cornall RJ., Single epitope multiple staining to detect ultralow frequency B cells. J Immunol Methods 2001; 249: 137-146.
29. Naito Y, Takematsu H, Koyama S, et al. Germinal center marker GL7 probes activation-dependent repression of N-glycolylneuraminic acid, a sialic acid species involved in the negative modulation of B-cell activation. Mol Cell Biol 2007; 27: 3008-3022.
30. Takahashi Y, Ohta H, Takemori T., Fas is required for clonal selection in germinal centers and the subsequent establishment of the memory B cell repertoire. Immunity 2001; 14: 181-192.
31. Falini B, Fizzotti M, Pucciarini A, et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells and activated T cells. Blood 2000; 95: 2084-2092.
32. Cattoretti G, Shaknovich R, Smith PM, Jack HM, Murty VV, Alobeid B., Stages of germinal center transit are defined by B cell transcription factor coexpression and relative abundance. J Immunol 2006; 177: 6930-6939.
33. Sciammas R, Shaffer AL, Schatz JH, Zhao H, Staudt LM, Singh H., Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation. Immunity 2006; 25: 225-236.
34. Sciammas R, Li Y, Warmflash A, Song Y, Dinner AR, Singh H., An incoherent regulatory network architecture that orchestrates B cell diversification in response to antigen signaling. Mol Syst Biol 2011; 7: 495.
35. Ochiai K, Maienschein-Cline M, Simonetti G, et al. Transcriptional regulation of germinal center B and plasma cell fates by dynamical control of IRF4. Immunity 2013; 23: 918-929.
36. Taylor JJ, Pape KA, Jenkins MK., A germinal center-independent pathway generates unswitched memory B cells early in the primary response. J Exp Med 2012; 209: 597-606.
37. Kaji T, Ishige A, Hikida M, et al. Distinct cellular pathways select germline-encoded and somatically mutated antibodies into immunological memory. J Exp Med 2012; 209: 2079-2097.
38. Hammerling GJ, Rusch E, Tada N, Kimura S, Hammerling U., Localization of allodeterminants on H-2Kb antigens determined with monoclonal antibodies and H-2 mutant mice. Proc Natl Acad Sci USA 1982; 79: 4737-4741.
39. Lemke H, Hammerling GJ., Clustering of antigenic determinants on H-2 molecules. J Immunol 1982; 128: 2465-2469.
40. Sherman LA, Chattopadhyay S, Biggs JA, Dick RF II, Bluestone JA., Alloantibodies can discriminate class I major histocompatibility complex molecules associated with various endogenous peptides. Proc Natl Acad Sci USA 1993; 90: 6949-6951.
41. Mulder A, Eijsink C, Kester MG, et al. Impact of peptides on the recognition of HLA class I molecules by human HLA antibodies. J Immunol 2005; 175: 5950-5957.
42. Smith RN, Kawai T, Boskovic S, et al. Chronic antibody mediated rejection of renal allografts: Pathological, serological and immunologic features in nonhuman primates. Am J Transplant 2006; 6: 1790-1798.
43. Colvin RB., Antibody-mediated renal allograft rejection: Diagnosis and pathogenesis. J Am Soc Nephrol 2007; 18: 1046-1056.
44. Wojciechowski D, Vincenti F., Belatacept for prevention of acute rejection in adult patients who have had a kidney transplant: An update. Biologics 2012; 6: 385-393.
45. Walker LS, Wiggett HE, Gaspal FM, et al. Established T cell-driven germinal center B cell proliferation is independent of CD28 signaling but is tightly regulated through CTLA-4. J Immunol 2003; 170: 91-98.
46. Nankivell BJ, Alexander SI., Rejection of the kidney allograft. N Engl J Med 2010; 363: 1451-1462.
47. Mengel M, Sis B, Haas M, et al. Banff 2011 Meeting report: New concepts in antibody-mediated rejection. Am J Transplant 2012; 12: 563-570.
48. Sis B, Jhangri GS, Riopel J, et al. A new diagnostic algorithm for antibody-mediated microcirculation inflammation in kidney transplants. Am J Transplant 2012; 12: 1168-1179.
49. Morrow WR, Frazier EA, Mahle WT, et al. Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients. Transplantation 2012; 93: 319-324.
50. Huber L, Lachmann N, Durr M, et al. Identification and therapeutic management of highly sensitized patients undergoing renal transplantation. Drugs 2012; 72: 1335-1354.